Navigation Links
Hospira Announces Executive Changes
Date:3/1/2013

LAKE FOREST, Ill., March 1, 2013 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that Royce R. Bedward has been appointed corporate vice president, general counsel and secretary, effective immediately. In his new role, Mr. Bedward will oversee the company's legal department, including litigation, benefits, labor and employment, intellectual property, governance, securities and transactional matters. He will report to Brian Smith , who has served as Hospira's senior vice president and general counsel since its spin-off in 2004, and now assumes the newly created role of chief legal officer, including responsibility for government affairs. Both Mr. Smith and Mr. Bedward will serve as members of the company's senior leadership team, led by F. Michael Ball , chief executive officer.

(Photo: http://photos.prnewswire.com/prnh/20130301/CG69263)

"Royce is an accomplished lawyer and integrity-driven business leader with more than 10 years of experience in the healthcare field and a proven track record of success at Hospira," said Mr. Ball. "We look forward to Royce's many additional contributions, while thanking Brian for his continued service and counsel. Working together, I'm confident that their strong leadership abilities will help position Hospira for a stronger future of sustainable, long-term growth and drive greater value for our stakeholders."

Mr. Bedward, 47, is one of the founding members of Hospira's legal leadership team, joining the company at its inception as its vice president of litigation, and assuming roles of increasing responsibility, most recently holding the position of deputy general counsel and secretary.  Prior to
'/>"/>

SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. Hospira Reports First-Quarter 2012 Results
3. Hospira to Present at Upcoming Investor Conferences
4. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
5. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
6. Hospira to Host Conference Call for Second-quarter 2012 Results
7. Hospira Expands Board of Directors With Election of Dennis M. Fenton
8. Hospira Reports Second-Quarter 2012 Results
9. Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
10. Hospira Reports Third-Quarter 2012 Results
11. Hospira to Present at the J.P. Morgan 31st Annual Healthcare Conference Jan. 8, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Landauer, Inc. (NYSE: LDR ), a recognized leader ... medical physics services and high quality medical consumable accessories, ... fiscal third quarter 2015 after the market close on ... will also host a conference call for investors on ... (10:00 a.m. Eastern Time). Investors may access the live ...
(Date:8/3/2015)... 3, 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapies for the treatment ... reported financial results for the three and six months ... , On July 23, 2015, the Committee for ... opinion for Zalviso™ for the management of acute moderate-to-severe ...
(Date:8/3/2015)... , Aug. 3, 2015  LEO Pharma supports ... Administration (FDA) to include psoriasis as one of eight ... Development Initiative i .  Psoriasis is an autoimmune disease ... subsequent comorbidities, affecting 7.5 million people in the US ... Pharma,s ongoing commitment to supporting patients living with psoriasis, ...
Breaking Medicine Technology:Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 2LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 3
... Inc.,(Nasdaq: ITMN ) today announced that it ... pirfenidone in idiopathic pulmonary fibrosis (IPF) prior,to market open ... conference,call and webcast, with accompanying slide presentation, to discuss ... a.m. PST) on Tuesday,February 3. , ...
... led by Laurie Ozelius, Ph.D. at Mount Sinai School ... development of primary torsion dystonia, also known as DYT6 ... Research Foundation (DMRF), Dr. Ozelius and her colleagues have ... dystonia in Amish-Mennonite families, as well as in other ...
Cached Medicine Technology:InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3 2Genetic Research Leads to New Discovery in Understanding Rare Neurological Disorder 2
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... date of its industry-defining contract lifecycle management solution, as well as announced the ... to increase the speed and ease of contract management tasks as well as ...
(Date:8/3/2015)... Alachua, FL (PRWEB) , ... August 03, 2015 , ... ... peripheral nerve injuries, is scheduled to present at the Wedbush Healthcare Conference on Wednesday, ... , A live webcast and subsequent archived replay of the Company’s presentation may be ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration (FDA) ... similar to deoxycholic acid, which occurs naturally in the body and helps absorb and ... this area of the body. These are invasive procedures and very expensive for most ...
(Date:8/3/2015)... ... August 03, 2015 , ... From 2006-2017 the number of ... to market research compiled for the National Association of Dental Laboratories ( NADL ... Bureau of Labor Statistics. As the number of dental laboratories decreases, dentists will ...
(Date:8/3/2015)... Ramon, CA (PRWEB) , ... August 03, 2015 ... ... leading global insurance brokerage firm, announced today that Joe Williams has joined its ... development, sales, and delivering HUB's differentiated service model to his clients. Mr. Williams ...
Breaking Medicine News(10 mins):Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... CITY)Research into how carbohydrates are converted into energy has ... treatment of a perplexing and potentially fatal neuromuscular disorder ... this study, the cause of this neuromuscular disorder was ... members who have the disorder, a team led by ...
... , THURSDAY, May 24 (HealthDay News) -- While fewer people ... of strokes has remained about the same, health officials report. ... nation,s so-called "stroke belt." According to the report on ... strokes dipped slightly from 2.7 percent to 2.6 percent during ...
... a new, higher-yield, two-step, less costly process that may ... material essential for making the mainstay drug for malaria. ... more than 1 million. The report on the process, ... implemented by drug companies, appears in ACS, journal ...
... most comprehensive analyses to date of the cost of robotic-assisted, ... this now-dominant surgical approach is significantly more costly than standard ... outcomes. The results of the study are available online and ... Urology . In one of the first studies ...
... The British Association for Psychopharmacology (BAP) has released ... abuse and addiction in the Journal of Psychopharmacology ... carefully researched the new, comprehensive guidelines, offering practitioners a ... their clinical decisions. The new BAP guidelines target ...
... May 22 (HealthDay News) -- New research suggests that ... anticholinergics -- such as ipratropium [Atrovent] -- could be ... irregular heartbeat. However, the increased risk was ... this finding raises concern because of the recent interest ...
Cached Medicine News:Health News:Pivotal role for proteins -- from helping turn carbs into energy to causing devastating disease 2Health News:Strokes More Common in Southern States: CDC 2Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 2Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 3Health News:British experts update addiction treatment guidelines 2Health News:Asthma Meds May Be Linked to Irregular Heartbeat 2
... low osmolar, nonionic, contrast media agent ... inert when injected intra-arterially. Each milliliter ... ioversol, 3.6 mg of tromethamine as ... edetate calcium disodium as a stabilizer. ...
... OMNIPAQUE is an X-ray ... adults and children for: angiography, ... and computed tomography of the ... Arthrography, endoscopic retrograde cholangio (pancreato) ...
... IMAGOPAQUE is a non-ionic monomeric contrast medium ... adults and children. After a decade of ... million examinations, IMAGOPAQUE has proven to be ... in hundreds of radiology departments.Results from large ...
... The only MR contrast agent FDA-approved for ... a gadolinium based, IV contrast media for ... liver. OptiMARK has convenient packaging options ... packaged for efficient, problem-free delivery. You can ...
Medicine Products: